XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.70

-3.6%

Jan 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (5123)	12/16/1997 4:42:00 AM
From: Tharos	Read Replies (3) of 17367

Bob, Apologies for forgetting, but Roche recently (within the last month or so) had Daclizumab (anti-CD 24 I think) approved by FDA for kidney transplants. Was this an independent project or are we expecting royalities from them? Daclizumab will be marketed under the trade name Zenapax.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next